Intrepid Financial Planning Group LLC Has $654,000 Holdings in Novo Nordisk A/S (NYSE:NVO)

Intrepid Financial Planning Group LLC lessened its stake in Novo Nordisk A/S (NYSE:NVO) by 35.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 7,608 shares of the company’s stock after selling 4,180 shares during the quarter. Intrepid Financial Planning Group LLC’s holdings in Novo Nordisk A/S were worth $654,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Center for Financial Planning Inc. boosted its holdings in shares of Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company’s stock worth $25,000 after buying an additional 123 shares during the period. Daiwa Securities Group Inc. acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at $28,000. Albion Financial Group UT increased its position in shares of Novo Nordisk A/S by 121.4% during the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after purchasing an additional 278 shares in the last quarter. Sound Income Strategies LLC increased its position in shares of Novo Nordisk A/S by 82.1% during the 4th quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock worth $46,000 after purchasing an additional 243 shares in the last quarter. Finally, Hager Investment Management Services LLC bought a new stake in Novo Nordisk A/S during the 4th quarter worth about $46,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Novo Nordisk A/S stock opened at $77.22 on Friday. The stock has a market capitalization of $346.54 billion, a price-to-earnings ratio of 23.47, a PEG ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a 52-week low of $73.80 and a 52-week high of $148.15. The stock’s 50 day moving average price is $83.95 and its two-hundred day moving average price is $103.01. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, equities analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be issued a dividend of $0.7874 per share. This represents a yield of 1.2%. The ex-dividend date is Monday, March 31st. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s payout ratio is presently 47.72%.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on NVO. BMO Capital Markets reduced their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Thursday. Finally, UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.